Aadi Bioscience, Inc.

Good day, and thank you for standing by. Welcome to the Addi Bioscience, Inc. second quarter 2024 earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1-1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1-1 again. Please be advised that today's conference is being recorded. Now I will turn the call over to Audrey Gross, head of corporate communications for Addi Bioscience. Ms. Gross, please go ahead.

Thank you.

Good morning and welcome to the Addi Bioscience conference call to provide an operational update and review results for the second quarter of 2024. We will be presenting slides as part of the live webcast of this call. Such slides will be posted on the investors and news page of the AddiBioScience website at addibio.com following the conference call. A quick reminder that statements made on the call today will include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties, and other factors, including those set forth in the risk factors section of our annual and quarterly filing with the Securities and Exchange Commission. which can be found at www.sec.gov or on our website at adibio.com. In addition, any forward-looking statements made on this call represent our views only as of today, August 7th, 2024, and should not be relied upon as representing our views as of any subsequent date. We specifically just claim any obligation to update or revise any forward-looking statements. On the call is Dr. Dave Lennon, our President and CEO, Scott Giacobbello, our CFO, and our Chief Medical Officer, Dr. Loretta Itri. Today, we will provide an overview of operational activity and financial results for the second quarter of 2024. We will then open the line for questions at the end of the call, following closing comments. I'll now turn the call over to Dave for his opening statement. Dave?